IP Verse

Tapentadol For Treating Pain Associated With Trigeminal Neuralgia - EP2694050

The patent EP2694050 was granted to Grnenthal on Oct 2, 2019. The application was originally filed on Apr 3, 2012 under application number EP12718065A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2694050

GRNENTHAL
Application Number
EP12718065A
Filing Date
Apr 3, 2012
Status
Opposition Rejected
Jun 2, 2023
Publication Date
Oct 2, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 2, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONDE102007012165
DESCRIPTIONEP0693475
DESCRIPTIONUS2005058706
DESCRIPTIONWO2008110323
EXAMINATIONWO2007025286
INTERNATIONAL-SEARCH-REPORTDE102007012165
OPPOSITIONDE102007012165
OPPOSITIONUS2008269326
OPPOSITIONUS2010227921
OPPOSITIONWO2007025286

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- GRUDT T J ET AL, "mu-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199403), Database accession no. NLM8126561
EXAMINATION- WILLIAMSON D J ET AL, "Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats.", BRITISH JOURNAL OF PHARMACOLOGY JUL 2001, (200107), vol. 133, no. 6, ISSN 0007-1188, pages 807 - 814
OPPOSITION- Anonymous, "The International Classification of Headache Disorders. 2nd Edition", Cephalagia An International Journal of Headache, (20040101), vol. 24, no. Supp 1, pages 126 - 135, XP055767288
OPPOSITION- IMAMURA, Y. et al., "Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats", Exp Brain Res, (19970000), vol. 116, pages 97 - 103, XP055839012
OPPOSITION- J. Zakrzewska, Et Al, "Medical management of trigeminal neuropathic pains", Expert Opin. Pharmacother, (20100101), vol. 11, no. 8, pages 1239 - 1254, XP055767285
OPPOSITION- Mila Etropolski, "Safety and tolerability of tapentadol extended release (ER) in patients with painful diabetic peripheral neuropathy (DPN): results of a randomized-withdrawal phase 3 study", American Diabetes Association, 69th Scientific Sessions, (20090101), pages 1 - 2, XP055767283
OPPOSITION- MOULIN, D.E. et al., "Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the Canadian Pain Society", Pain Red Manage, (20070000), vol. 12, no. 1, pages 13 - 21, XP055839016
OPPOSITION- SCHRÖDER, W. et al., "Differential contribution of opioid noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain", European Journal of Pain, (20100000), vol. 14, pages 814 - 821, XP027224271
OPPOSITION- Timothy Grudt, Williams, John T, "µ-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat", The Journal of Neuroscience, (19940301), vol. 14, no. 3, pages 1646 - 1654, XP055767291
OPPOSITION- TZSCHENTKE, T. M. et al., "Tapentadol: mit zwei mechanismen in einem Molekül wirksam gegen nozizeptive und neuropathische schmerzen", Schmerz, (20110000), vol. 25, doi:10.1007/s00482-010-1004-1, pages 19 - 25, XP009149538
OPPOSITION- SHOU et al., "Oral ralfinamide suppresses autonomy following hindpaw deafferation by multiple dorsal rhizotomies, a rat model of CNS-mediated spontaneous neuropathic pain", European Journal of Pain, (20090000), vol. 13, XP026680911
OPPOSITION- CHRISTOPH, T. et al., "Anti-allodynic activity of tapentadol in a rat model of neuropathic pain depends on opioid and noradrenergic, but not serotonergic , mechanisms", European Journal of Pain, (20090000), vol. 13, page S 205, XP026681308
OPPOSITION- WILLIAMSON, D. J., "Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats", British J. Pharmacol., (20010000), XP055651623
OPPOSITION- JAGGI, A. S., "Animal models of neuropathic pain", Fundamental & Clinical Pharmacology, (20110225), doi:10.1111/j.1472-8206.2009.00801.x, pages 1 - 28, XP055168812
OPPOSITION- TZSCHENTKE, T. M. et al., "1)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl- propyl)phenol Hydrochloride (Tapentadol HCl): a Novel Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties", The Journal Of Pharmacology And Experimental Therapeutics, (20070000), vol. 323, no. 1, doi:10.1124/JPET.107.126052, pages 265 - 276, XP002672360

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents